4x3r
From Proteopedia
(Difference between revisions)
												
			
			| Line 3: | Line 3: | ||
<StructureSection load='4x3r' size='340' side='right'caption='[[4x3r]], [[Resolution|resolution]] 1.86Å' scene=''>  | <StructureSection load='4x3r' size='340' side='right'caption='[[4x3r]], [[Resolution|resolution]] 1.86Å' scene=''>  | ||
== Structural highlights ==  | == Structural highlights ==  | ||
| - | <table><tr><td colspan='2'>[[4x3r]] is a 1 chain structure with sequence from [  | + | <table><tr><td colspan='2'>[[4x3r]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4X3R OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4X3R FirstGlance]. <br>  | 
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=686:N-({(1S)-5-[(4-BROMOBENZYL)({6-[4-(4-{4-[4-CARBOXY-3-(6-HYDROXY-3-OXO-3H-XANTHEN-9-YL)BENZOYL]PIPERAZIN-1-YL}PHENYL)PIPERAZIN-1-YL]PYRIDIN-3-YL}CARBONYL)AMINO]-1-CARBOXYPENTYL}CARBAMOYL)-L-GLUTAMIC+ACID'>686</scene>, <scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene  | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=686:N-({(1S)-5-[(4-BROMOBENZYL)({6-[4-(4-{4-[4-CARBOXY-3-(6-HYDROXY-3-OXO-3H-XANTHEN-9-YL)BENZOYL]PIPERAZIN-1-YL}PHENYL)PIPERAZIN-1-YL]PYRIDIN-3-YL}CARBONYL)AMINO]-1-CARBOXYPENTYL}CARBAMOYL)-L-GLUTAMIC+ACID'>686</scene>, <scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>  | 
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4x3r FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4x3r OCA], [https://pdbe.org/4x3r PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4x3r RCSB], [https://www.ebi.ac.uk/pdbsum/4x3r PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4x3r ProSAT]</span></td></tr>  | |
| - | + | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[  | + | |
</table>  | </table>  | ||
== Function ==  | == Function ==  | ||
| - | [  | + | [https://www.uniprot.org/uniprot/FOLH1_HUMAN FOLH1_HUMAN] Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Isoform PSM-4 and isoform PSM-5 would appear to be physiologically irrelevant. Involved in prostate tumor progression.  Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.  | 
<div style="background-color:#fffaf0;">  | <div style="background-color:#fffaf0;">  | ||
== Publication Abstract from PubMed ==  | == Publication Abstract from PubMed ==  | ||
| Line 27: | Line 25: | ||
__TOC__  | __TOC__  | ||
</StructureSection>  | </StructureSection>  | ||
| - | [[Category:   | + | [[Category: Homo sapiens]]  | 
| - | + | ||
[[Category: Large Structures]]  | [[Category: Large Structures]]  | ||
| - | [[Category: Konvalinka  | + | [[Category: Konvalinka J]]  | 
| - | [[Category: Tykvart  | + | [[Category: Tykvart J]]  | 
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
Revision as of 21:10, 12 April 2023
Avi-GCPII structure in complex with FITC-conjugated GCPII-specific inhibitor
  | |||||||||||
